Journal of Clinical Endocrinology & Metabolism, Vol 80, 2014-2020, Copyright © 1995 by Endocrine Society

ARTICLES

Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency

AB Mercado, RC Wilson, KC Cheng, JQ Wei and MI New
Department of Pediatrics, New York Hospital-Cornell Medical Center, New York 10021, USA.

Since 1986, prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD) have been carried out in 239 pregnancies. In 145, diagnoses were made by amniocentesis, whereas 77 were diagnosed using chorionic villus sampling. A newly developed, rapid allele-specific polymerase chain reaction was used for DNA analysis in some cases. Of 239 pregnancies evaluated, 37 babies were affected with classical 21-OHD. Of these, 21 were females, 13 of whom were treated prenatally with dexamethasone. Dexamethasone administered at or before 10 weeks gestation (9 affected female fetuses) was effective in reducing virilization. Seven fetuses had affected female siblings (Prader stages 1-5); 3 of these were born with entirely normal female genitalia, whereas the other 4 were significantly less virilized (Prader stages 1-2) than their siblings. The remaining 2 newborns had male siblings; 1 was born with normal genitalia, and the other was Prader stage 1. No significant or enduring side-effects were noted in either the mothers or the fetuses, indicating that dexamethasone treatment is safe. Prenatally treated newborns did not differ in weight, length, or head circumference from untreated unaffected newborns. Based on our experience, proper prenatal diagnosis and treatment of 21-OHD is effective in significantly reducing or eliminating virilization in the affected female. This spares the newborn female the consequences of genital ambiguity, i.e. genital surgery, sex misassignment, and gender confusion.

This article has been cited by other articles:

				T. Hirvikoski, A. Nordenstrom, T. Lindholm, F. Lindblad, E M. Ritzen, and S. Lajic Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? Eur. J. Endocrinol., September 1, 2008; 159(3): 309 - 316. [Abstract] [Full Text] [PDF]

				M. J. De Blasio, M. Dodic, A. J. Jefferies, K. M. Moritz, E. M. Wintour, and J. A. Owens Maternal exposure to dexamethasone or cortisol in early pregnancy differentially alters insulin secretion and glucose homeostasis in adult male sheep offspring Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E75 - E82. [Abstract] [Full Text] [PDF]

				T. Hirvikoski, A. Nordenstrom, T. Lindholm, F. Lindblad, E. M. Ritzen, A. Wedell, and S. Lajic Cognitive Functions in Children at Risk for Congenital Adrenal Hyperplasia Treated Prenatally with Dexamethasone J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 542 - 548. [Abstract] [Full Text] [PDF]

				H. F. L. Meyer-Bahlburg, C. Dolezal, S. W. Baker, A. D. Carlson, J. S. Obeid, and M. I. New Cognitive and Motor Development of Children with and without Congenital Adrenal Hyperplasia after Early-Prenatal Dexamethasone J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 610 - 614. [Abstract] [Full Text] [PDF]

				M. I. New, A. Carlson, J. Obeid, I. Marshall, M. S. Cabrera, A. Goseco, K. Lin-Su, A. S. Putnam, J. Q. Wei, and R. C. Wilson EXTENSIVE PERSONAL EXPERIENCE: Prenatal Diagnosis for Congenital Adrenal Hyperplasia in 532 Pregnancies J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5651 - 5657. [Abstract] [Full Text] [PDF]

				P. F. Collett-Solberg Congenital Adrenal Hyperplasia: From Genetics and Biochemistry to Clinical Practice, Part 2 Clinical Pediatrics, March 1, 2001; 40(3): 125 - 132. [Abstract] [PDF]

				Section on Endocrinology and Committee on Genetics Technical Report: Congenital Adrenal Hyperplasia Pediatrics, December 1, 2000; 106(6): 1511 - 1518. [Abstract] [Full Text]

				P. C. White and P. W. Speiser Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Endocr. Rev., June 1, 2000; 21(3): 245 - 291. [Abstract] [Full Text]

				H.-H. Lee, J.-G. Chang, C.-H. Tsai, F.-J. Tsai, H.-T. Chao, and B.-c. Chung Analysis of the Chimeric CYP21P/CYP21 Gene in Steroid 21-Hydroxylase Deficiency Clin. Chem., May 1, 2000; 46(5): 606 - 611. [Abstract] [Full Text] [PDF]

				C G D Brook;, I. HUGHES;, and C. J H KELNAR Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2000; 82(3): 176F - 181. [Full Text]

				H.-H. Lee, J.-M. Kuo, H.-T. Chao, Y.-J. Lee, J.-G. Chang, C.-H. Tsai, and B.-c. Chung Carrier Analysis and Prenatal Diagnosis of Congenital Adrenal Hyperplasia Caused by 21-Hydroxylase Deficiency in Chinese J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 597 - 600. [Abstract] [Full Text]

				S. A. Berenbaum, S. C. Duck, and K. Bryk Behavioral Effects of Prenatal Versus Postnatal Androgen Excess in Children with 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 727 - 733. [Abstract] [Full Text]

				M. I. New and R. C. Wilson Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess PNAS, October 26, 1999; 96(22): 12790 - 12797. [Abstract] [Full Text] [PDF]

				B. I. Cerame, R. S. Newfield, L. Pascoe, K. M. Curnow, S. Nimkarn, T. F. Roe, M. I. New, and R. C. Wilson Prenatal Diagnosis and Treatment of 11{beta}-Hydroxylase Deficiency Congenital Adrenal Hyperplasia Resulting in Normal Female Genitalia J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3129 - 3134. [Abstract] [Full Text]

				S. A. Wudy, H. G. Dörr, C. Solleder, M. Djalali, and J. Homoki Profiling Steroid Hormones in Amniotic Fluid of Midpregnancy by Routine Stable Isotope Dilution/Gas Chromatography-Mass Spectrometry: Reference Values and Concentrations in Fetuses at Risk for 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2724 - 2728. [Abstract] [Full Text]

				T. Tajima, X.-M. Ma, S. R. Bornstein, and G. Aguilera Prenatal Dexamethasone Treatment Does Not Prevent Alterations of the Hypothalamic Pituitary Adrenal Axis in Steroid 21-Hydroxylase Deficient Mice Endocrinology, July 1, 1999; 140(7): 3354 - 3362. [Abstract] [Full Text]

				H. F. L. Meyer-Bahlburg What Causes Low Rates of Child-Bearing in Congenital Adrenal Hyperplasia? J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1844 - 1847. [Full Text]

				J. C. Lo, V. M. Schwitzgebel, J. B. Tyrrell, P. A. Fitzgerald, S. L. Kaplan, F. A. Conte, and M. M. Grumbach Normal Female Infants Born of Mothers with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 930 - 936. [Abstract] [Full Text]

				S. Lajic, A. Wedell, T.-H. Bui, E. M. Ritzén, and M. Holst Long-Term Somatic Follow-Up of Prenatally Treated Children with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3872 - 3880. [Abstract] [Full Text]

				N. Krone, A. A. Roscher, H. P. Schwarz, and A. Braun Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency Clin. Chem., October 1, 1998; 44(10): 2075 - 2082. [Abstract] [Full Text] [PDF]

				J. R. Seckl and W. L. Miller How Safe Is Long-term Prenatal Glucocorticoid Treatment? JAMA, April 2, 1997; 277(13): 1077 - 1079. [Abstract] [PDF]